胃泌素类似物的人工合成和泌酸活性研究

本文采用液相合成法合成了九种胃泌素类似物,并用大白鼠胃灌流技术测定其泌酸活性。若以五肽胃泌素(Boc-β-Ala-Trp-Met-Asp-phe-NH_2,Boc-五肽)的泌酸活性为100％,则胃泌其它类似物的活性分别为:Boc-四肽(Boc-Trp-Met-Asp-Phe-NH_2)30.32％,Boc-三肽(Boc-Met-Asp-phe-NH_2)0.13％;Fmoc-五肽(Fmoc-β-Ala-Trp-Met-ASP-Phe-NH_2)171％,Fmoc-四肽(Fmco-Trp-Met-Asp-Phe-NH_2)32.88％,Fmoc-三肽·(Fmoc-Met-Asp-Phe-NH_2)0.17％,五肽·TFA(β-Ala-Trp-Met-Asp-Phe-NH_2·TFA)17.45％,四肽·TFA(Trp-Met-Asp-phe-NH_2·TFA)5.58％。 实验结果显示四肽胃泌素类似物的活性这比三肽的高,表明胃泌素C-端片段中色氨酸残基对泌酸活性十分重要。在胃泌素类似物的N-端导入保护基同样提高它们的生物学活性,而Fmoc-保护基的作用还强于Boc-保护性。推测其主要原因是在N-式加上一个疏水性强的基团后有利于形成一个与受体相结合的活性构象。     

虎纹捕鸟蛛毒素-Ⅰ的化学合成及其结构与生理活性分析

应用芴甲氧羰基(Fmoc)固相方法化学合成了虎纹捕鸟蛛毒素-I,合成采用Fmoc氨基酸五氟苯酯,各侧链保护措施如下:羧基和酚羟基用叔丁基(tBu)保护,赖氨酸和组氨酸侧链用叔丁氧羰基(Boc)保护,精氨酸胍基用4-甲氧-2,3,6-三甲基苯磺酰基(Mtr)保护,半胱氨酸巯基用三苯甲基(Trt)保护.固相载体为需活化的乙二胺-聚乙二醇-聚苯乙烯(EDA-PEG-PS)树脂.合成产物(肽树脂)用苯甲硫醚-乙二硫醇-苯甲醚-三氟乙酸系统一步裂解以及去除侧链保护基,然后用二硫苏糖醇(DTT)还原,再通过氧化型和还原型谷胱甘肽系统促使其形成正确的二硫键配对.对HPLC分离纯化得到的合成产物,进行了氨基酸组成、肽谱、氨基酸顺序以及一维核磁共振谱分析.分析结果表明合成毒素具有与天然毒素相同的化学结构和空间构象.生理实验结果表明,其生物学活性与天然Huwentoxin-I也相同.     

八肽胆囊收缩素(CCK_8)的人工合成

本文报道了用液相法合成八肽胆囊收缩素(H-Asp-Tyr(SO_3H)-Met-Gly-Trp-Met-Asp-Phe-NH_2,ccK_8)。先分别合成C-端四肽和N-端四肽,然后缩合成八肽,并用温和的乙酰硫酸吡啶盐(PAS)法使其酪氨酸的酚羟基硫酯化。根据其氨基酸组成,层析行为和生物活性等证实产物为纯品。     

猪脑抗吗啡镇痛肽的分离纯化及其抗血清对吗啡耐受影响的初步研究

猪脑组织提取液经SephadexG-50分子筛层析,S-SepharoseFastFlow阳离子交换柱层析及两次HPLC分离得到一分子量为12000,等电点pI7．1的多肽,并测定了其氨基酸组成和N末端部分序列：N-phe-Lys-Gly-Phe-Pro-Asp-Asp／（Lys）-Lys／（Asp）-Asp-Tyr．给昆明小鼠脑室注射或尾静脉注射该肽均能抑制吗啡引起的镇痛作用,其作用随着注射剂量的增大而增强．用BALB／C小鼠制备了该肽的抗血清,脑室注射此抗血清能明显逆转昆明小鼠对吗啡的耐受．因为这种来自猪脑的具有抗阿片镇痛作用的肽有99个氨基酸,所以简称此肽为AOP-99a（anti-oPioidpeptide）．     

固相法合成多肽AN-M的工艺研究

目的:探讨生物活性肽AN-M的固相合成工艺,并为工业化合成目的肽提供理论依据。方法采用固相法,以Fmoc-保护基保护的α-氨基酸和Wang树脂为原料,经1—氧—3—双二甲胺羧基苯骈三氮唑四氟化硼盐(TBTU)、1—羟基苯并三氮唑(HoBt)、二异丙基乙胺(DIEA)缩合,20%哌啶的DMF溶液脱保护,用切割试剂将AN-M粗品从Wang树脂上切割下来。结果经反相高效液相色谱分析纯化,可得目的肽的得率大于67．00%,最终成品的纯度在98．78%以上,经质谱鉴定其分子量与理论值一致。结论该合成方法步骤简便、便于操作、产品得率高,可用于大规模合成目的肽。     

化学法合成RGD三肽的研究

采用二环己基碳二亚胺法（DCC）合成了二肽Gly-Asp（OBzl）2,然后利用混合酸酐法得到全保护RGD三肽：Boe-Arg（Nq）-Gly-Asp（OBzl）2三肽;最后在Pd／C的催化加氢下,将保护基一起脱掉而得到RGD三肽的粗品。具体研究了合成二肽及三肽的主要影响因素及其优化条件。在优化条件下,获得三肽的结晶干品,总得率为57.2％。     

两种树脂固相合成机体保护肽的比较

目的:比较Wang树脂和二氯三苯甲基树脂(以下简称二氯树脂)在固相合成机体保护肽中的表现,为工业化生产提供理论依据。方法:通用的Fmoc固相合成法制备机体保护肽,通过比色法对两种树脂与氨基酸的偶联率进行比较,用质谱(MALDI-TOFMS)对粗肽进行鉴定分析,用反相高效液相色谱(RP-HPLC)进行粗肽的分析和纯化。结果:显示以二氯树脂作载体,第一个氨基酸的连接率,以及机体保护肽的纯度和产率都要明显高于Wang树脂。结论:二氯树脂作载体合成机体保护肽更适合大规模工业化生产的要求。     

降钙素基因相关肽的合成

降钙素基因相关肽是一个包含有37个氨基酸残基的具有较强降血压生理功能的活性多肽。我们采用常规的固相合成方法,以简单的装置最后经无水氟化氢处理,将肽从树脂上切下,同时脱除所有侧链保护基。粗产物在30％乙酸溶液中用碘作为氧化剂使二个半胱氨酸氧化,形成二硫键。合成的α-人降钙素基因相关肽经反向高效液相层析分离,获得在高效液相层析为单一峰的产物。经酸水解氨基酸分析证明与理论值相符并具有全部生理活性。     

生物活性肽SSDI固相合成工艺的研究

目的:研究生物活性肤SSDI的固相合成工艺,并为大规模合成目标肽提供理论依据.方法:采用固相合成法,原料氨基酸以Fmoe形式保护,用Wang树脂为载体,经1-氧3-双二甲胺羰基苯骈三氮唑四氟化硼盐(TBTU)\1-羟基-苯并-三氮唑(HOBt)\二-异丙基乙胺(DIEA)混合试剂缩合,20%哌啶的DMF溶液脱保护,用三氟乙酸\茴香硫醚\巯基乙醇\苯酚\水混合作为切割试剂将多肽从Wang树脂上切割下来.结果:多肽粗品的得率高达70%,经RP-HPLC纯化,可获得纯度在98%以上的目标肽,经MALDI-MS质谱鉴定其分子量与理论值一致.结论:此合成方法操作简单,产品得率高,适合大规模合成目标肽.     

人胰岛素原C肽固相合成的改进

利用谷氨酸的γ羧基与 4 甲基二苯甲基胺 (MBHA)树脂的氨基偶联固相 ,合成经HF切割去保护基后形成C端是谷氨酰胺的人胰岛素原C肽。MBHA树脂相对价格便宜 ,此方法是制备人胰岛素原C肽的另一种尝试。同时 ,也用PAM树脂合成了人胰岛素原C肽类似物。     

内吗啡肽-2的人工合成及其酶促降解

内吗啡肽-2(endomorphin-2)是Zadina等人[1]于1997年发现的一种具有镇痛作用的四肽,它存在于动物和人的中枢神经系统内[2].它是内源性μ阿片受体的激动剂,具有高亲合性(K1=690pmol,L)和选择性(δ/μ=13400、K/μ=7600).     

Synthesis of S-alkyl and C-terminal analogs of the Saccharomyces cerevisiae a-factor. Influence of temperature on the stability of Fmoc and OFm groups toward HF

The a-mating factor of Saccharomyces cerevisiae Tyr-Ile-Ile-Lys-Gly-Val-Phe-Trp-Asp-Pro-Ala-Cys(farnesyl)OCH3, and 10 analogs modified at the cysteine side chain and/or the terminal carboxyl were synthesized using a combination of solid phase and solution phase methodologies. The strategy of synthesis involved the condensation of an amine terminal protected decapeptide with a carboxyl terminal S-alkylated dipeptide ester or amide using benzotriazol-l-yloxy-tris(methylamino)-phosphonium hexafluorophosphate as the coupling agent. The protected decapeptide was assembled on a PAM-resin using 9-fluorenylmethoxycarbonyl (Fmoc) for the protection of the Tyr alpha-amine and Lys epsilon-amine and 9-fluorenylmethyl ester (OFm) for the protection of the Asp beta-carboxyl. Premature loss of the OFm group from the HF cleavage was observed at 0-2 degrees, whereas no loss occurred when the cleavage reaction was conducted at -5 degrees. In contrast to these results, the OFm group in Asp(OFm) was partially removed by HF at -5 degrees and was completely stable to HF only at -20 degrees. The S-alkylated dipeptide esters were prepared, in yields from 64% to 88%, via thioalkylation of amine protected or unprotected dipeptide esters using potassium fluoride dihydrate as the base. The use of a tertiary amine as the base of thiohexadecanylation resulted in low reactivity.     

Polypeptide synthesis by the thioester method

A novel method for polypeptide synthesis, in which partially protected peptide thioesters are used as building blocks, has been developed. Partially protected peptide thioesters are easily prepared by solid-phase methodology. The thioester moiety is converted to an active ester in the presence of a silver compound such as AgNO(3) or AgCl and an active ester component such as 1-hydroxybenzotriazole or 3,4-dihydro-3-hydro-4-oxo-1,2, 3-benzotriazine. Segment condensation can be accomplished using partially protected peptide segments. The consecutive condensation of the partially protected peptide segments is realized by the selective removal of the 9-flourenylmethoxycarbonyl group, for terminal amino protection, after segment condensation has been achieved. In this method, large peptide segments can easily be used. Thus, the products obtained by the thioester method can be separated from by-products by reverse phase high performance liquid chromatography, even when no purification process was performed during the prior segment condensation procedures. This indicates that proteins that have no specific features such as enzymatic or biological activities can be obtained after isolation, solely based on their chromatographic profiles. Thus, the thioester method will provide a new basis for protein studies including phosphorylated and glycosylated polypeptides.     

Isolation and characterization of the bovine hypothalamic corticotropin-releasing factor

A 41 amino acid peptide with high intrinsic corticotropin-releasing activity was isolated from 1000 bovine hypothalami by means of immunoaffinity chromatography, gel filtration, and two steps of reverse phase HPLC. The primary structure of the amino terminal 39 amino acids was characterized by gas phase sequence analysis. The sequence of the amidated carboxyl terminal dipeptide was established by digestion of the intact natural product with Staphylococcus aureus V8 protease, dansylation of the digest and comparative reverse phase liquid chromatography studies with the synthetic dansylated dipeptides Ile-Ala-NH2, Ile-Ala-OH, Ala-Ile-NH2 and Ala-Ile-OH. The complete structure of the bovine corticotropin-releasing factor was established as: Ser-Gln-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val- Leu- Glu-Met-Thr-Lys-Ala-Asp-Gln-Leu-Ala-Gln-Gln-Ala-His-Asn-Asn-Arg-Lys-Leu- Leu- Asp-Ile-Ala-NH2 using approximately 650 pmol of material.     

Influence of degradation on binding properties and biological activity of endomorphin 1

The recently-isolated endogenous peptide endomorphin 1 has high affinity for the mu opioid receptor and plays an important role in analgesia. Several of its degradation products have been isolated from the central nervous system. Degradation products present structural similarities and may influence the receptor binding properties and biological activity of the parent compound. Therefore, we investigated how degradation of endomorphin 1 might influence ligand binding to the mu opioid receptor, the consequent activation of G proteins and its antinociceptive effect. Both N- and C-terminal truncation of endomorphin 1 resulted in peptides presenting considerably lower opioid receptor binding potency. None of these peptides had an effect on GTP binding, nor was able to produce analgesia, suggesting that degradation destroys the biological activity of endomorphin 1.     

Analgesia induced by N-acetylserotonin in the central nervous system

The relationship between N-acetylserotonin (NAS) in the central nervous system (CNS) and responses to pain was investigated. Using the rat tail-flick model, we initially replicated the work of others showing that intraventricular (IVC) injection of a dipeptide structurally similar to both NAS and serotonin was capable of inducing analgesia in the rat. We then showed that IVC-NAS, but not serotonin elicited analgesia in much the same manner as the dipeptide. This effect proved to be very specific as it required the presence of both an acetyl group on the terminal side chain amine as well as a hydroxyl group on the C-5 position of the indole ring. Substitution of the C-5 hydroxyl by a methoxyl group (melatonin) abolished the analgesic effect. Similarly, removing the N-acetyl substitution (serotonin) also eliminated the analgesia. IVC injection of highly specific antiserum to NAS induced hyperalgesia. Furthermore, an interaction was found between NAS and opiate systems. We demonstrated that while naloxone, the opiate antagonist, has no hyperalgesic properties of itself, it did counteract the analgesia induced by NAS. Similarly, NAS antiserum reversed the analgesia induced by the opiate morphine. This work provides evidence that NAS is an endogenously active substance within the CNS pain network.     

Solution‐phase submonomer diversification of aza‐dipeptide building blocks and their application in aza‐peptide and aza‐DKP synthesis

Aza‐peptides have been used as tools for studying SARs in programs aimed at drug discovery and chemical biology. Protected aza‐dipeptides were synthesized by a solution‐phase submonomer approach featuring alkylation of N‐terminal benzophenone semicarbazone aza‐Gly‐Xaa dipeptides using different alkyl halides in the presence of potassium tert‐butoxide as base. Benzophenone protected aza‐dipeptide tert‐butyl ester 31c was selectively deprotected at the C‐terminal ester or N‐terminal hydrazone to afford, respectively, aza‐dipeptide acid and amine building blocks 36c and 40c, which were introduced into longer aza‐peptides. Alternatively, removal of the benzophenone semicarbazone protection from aza‐dipeptide methyl esters 29a–c led to intramolecular cyclization to produce aza‐DKPs 39a–c. In light of the importance of aza‐peptides and DKPs as therapeutic agents and probes of biological processes, this diversity‐oriented solution‐phase approach may provide useful tools for studying peptide science. Copyright © 2010 European Peptide Society and John Wiley & Sons, Ltd.     

Analgesic effects of N-acetyl-5HTP-5HTP amide are not directly related to brain serotonin levels.

A synthetic dipeptide, N-acetyl-5-hydroxytryptophyl-5-hydroxytryptophan amide, was shown previously to inhibit the binding of serotonin to a soluble specific serotonin binding protein as well as to alter brain serotonin levels. When injected into rats intraventricularly, the dipeptide caused an increase in pain threshold, lasting for several hours, as determined by either a flinch-jump test or a tail-flick test. This effect was reversed by naloxone. The dipeptide is a very weak inhibitor of the binding of labelled naloxone or dihydromorphine to a membranous opiate receptor preparation. The analgesic activity of the dipeptide was not diminished by p-chlorophenylalanine or the setonergic neurotoxin 5,7-dihydroxytryptamine, which depleted brain serotonin levels. This implies that the analgesic action of the dipeptide is not mediated directly by its effect on serotonin concentration.     

Solution phase synthesis of Saccharomyces cerevisiae a-mating factor and its analogs

The solution phase synthesis of the Saccharomyces cerevisiae a-mating factor and nonfarnesylated and nonmethylated a-factor analogs are reported. The a-factor, a lipopeptide with the sequence Tyr-Ile-Ile-Lys-Gly-Val-Phe-Trp-Asp-Pro-Ala-Cys(S-Farnesyl)OCH3 was synthesized by the condensation of the amine terminal protected decapeptide with the carboxyl terminal farnesylated dipeptide using benzotriazol-l-yloxy-tris-(dimethylamino)-phosphonium hexafluorophosphate (BOP reagent) as the coupling agent. The synthesis of the decapeptide involved 5 + 5 fragment coupling with the BOP reagent and the successful application of 9-fluorenylmethyl ester(OFm) and 9-fluorenylmethoxycarbonyl(Fmoc) groups for the protection of Asp and Lys side chains and Tyr alpha-amine and of phenacyl esters (OPa) for alpha-carboxyl protection. The OFm and Fmoc groups tolerated repeated couplings and were completely stable to zinc powder in acetic acid, a condition under which the OPa group was removed. The synthesis of the nonfarnesylated alpha-factor was accomplished by the coupling of the decapeptide with tetrapeptide (Ala-CysOCH3)2 followed by the deprotection of the OFm and Fmoc groups with piperidine and the cleavage of the disulfide bond with zinc powder in acetic acid. The nonmethylated a-factor was prepared by 10 + 2 fragment coupling using OFm protection of the dipeptide carboxyl group followed by removal of all protecting groups with piperidine. Attempts to saponify a-factor were not successful. The synthetic nonfarnesylated and nonmethylated a-mating pheromones were 100-1000 times less active than the a-factor, indicating that although the methyl ester and the farnesyl group are not essential for biological activity, they are necessary for high potency.     

Conformational perturbations in retro-analogs of the tBuCO-Ala-Gly-NHiPr dipeptide. Crystal structure of the retro-dipeptide with a reversed Ala-Gly amide bond

The three retro-analogs of the tBuCO-Ala-Gly-NHiPr dipeptide, in which each amide bond had been successively reversed, were studied in solution by 1H-n.m.r. and i.r. spectroscopy with reference to the conformational properties of their parent dipeptide. Reversal of the Ala-Gly amide bond proved to perturb the folding tendency of the backbone less than the inversion of either of the terminal amide bonds. The crystal structure of the retro-peptide containing a reversed Ala-Gly amide bond was also solved by X-ray diffraction and constitutes the first available data for this retro-peptide series. In contrast to the beta II-folded structure of the parent dipeptide, the retro-peptide molecule adopts an open conformation in the crystal.